The present application relates to a method for extracting coenzyme Q10 and a phospholipid from a coenzyme Q10 fermentation bacterium powder. The method is characterized in that the fermentation bacterium powder of a coenzyme Q10 production strain is subjected to extraction with a mixed solvent of which the three-dimensional Hansen solubility parameter is between 21 and 23 (J/cm.sup.3).sup.1/2 and the hydrogen bonding solubility parameter thereof is between 10 and 12 (J/cm.sup.3).sup.1/2. The present invention can efficiently extract two products, namely coenzyme Q10 and a phospholipid, from the coenzyme Q10 fermentation bacterium powder; the process thereof is highly operable, easy to be industrialized, and can provide a product with high purity and yield, having great economic benefit.

The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.

The present invention relates to a cocrystal of ubiquinone and a hydrogen bond donor coformer, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The invention also relates to compositions comprising the cocrystal.

The present invention relates to a cocrystal of ubiquinone and a hydrogen bond donor coformer, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The invention also relates to compositions comprising the cocrystal.

To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells.

A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II):

##STR00001## wherein in formula (I), R.sup.1 represents a C.sub.1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12,
or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.

To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells.

A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II):

##STR00001## wherein in formula (I), R.sup.1 represents a C.sub.1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12,
or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.

Described are methods and compositions for inhibiting polymerization of a monomer (e.g., styrene) composition using a hydroxylated quinone antipolymerant. The hydroxylated quinone antipolymerant can be used with little or no nitroxyl group containing antipolymerant yet still provide excellent antipolymerant activity in a monomer-containing composition.